Bacil Pharma [BACPHAR] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Bacil Pharma Ltd.

BSE
Loading...

Divi's Laboratories Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Bacil Pharma Ltd. wins in 3 metrics, Divi's Laboratories Ltd. wins in 13 metrics, with 1 ties. Divi's Laboratories Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Bacil Pharma Ltd. Divi's Laboratories Ltd. Better
P/E Ratio (TTM) 118.00 67.11 Divi's Laboratories Ltd.
Price-to-Book Ratio 3.09 10.82 Bacil Pharma Ltd.
Debt-to-Equity Ratio 0.00 0.58 Tie
PEG Ratio -0.91 4.63 Divi's Laboratories Ltd.
EV/EBITDA -312.09 48.63 Divi's Laboratories Ltd.
Profit Margin (TTM) 134.64% 24.04% Bacil Pharma Ltd.
Operating Margin (TTM) -39.22% 29.65% Divi's Laboratories Ltd.
EBITDA Margin (TTM) N/A 29.65% N/A
Return on Equity 1.59% 14.64% Divi's Laboratories Ltd.
Return on Assets (TTM) 1.58% 12.94% Divi's Laboratories Ltd.
Free Cash Flow (TTM) $4.01M $2.15B Divi's Laboratories Ltd.
Dividend Yield N/A 0.91% N/A
1-Year Return 10.61% -0.43% Bacil Pharma Ltd.
Price-to-Sales Ratio (TTM) 154.56 16.18 Divi's Laboratories Ltd.
Enterprise Value $754.34M $1,635.46B Divi's Laboratories Ltd.
EV/Revenue Ratio 137.68 15.86 Divi's Laboratories Ltd.
Gross Profit Margin (TTM) N/A 63.71% N/A
Revenue per Share (TTM) $0 $388 Divi's Laboratories Ltd.
Earnings per Share (Diluted) $0.50 $93.66 Divi's Laboratories Ltd.
Beta (Stock Volatility) 0.55 0.19 Divi's Laboratories Ltd.

Bacil Pharma Ltd. vs Divi's Laboratories Ltd. Stock Performance Analysis

Loading Price Chart...

BACPHAR
DIVISLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Bacil Pharma Ltd.-9.98%-20.59%-30.97%-19.51%0.92%5.05%
Divi's Laboratories Ltd.-0.44%1.34%-2.25%8.85%4.11%4.17%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Bacil Pharma Ltd.10.61%366.06%494.15%1,158.50%1,113.06%494.15%
Divi's Laboratories Ltd.-0.43%85.44%58.15%496.33%1,610.60%10,946.76%

Performance & Financial Health Analysis: Bacil Pharma Ltd. vs Divi's Laboratories Ltd.

MetricBACPHARDIVISLAB
Market Information
Market Cap i₹804.20M₹1.69T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i5,580253,443
90 Day Avg. Volume i15,293283,911
Last Close₹39.31₹6,608.50
52 Week Range₹26.69 - ₹61.80₹5,636.50 - ₹7,071.50
% from 52W High-36.39%-6.55%
All-Time High₹62.56 (Dec 16, 2024)₹7,071.50 (Jul 08, 2025)
% from All-Time High-37.16%-6.55%
Growth Metrics
Quarterly Revenue GrowthN/A0.12%
Quarterly Earnings GrowthN/A-0.01%
Financial Health
Profit Margin (TTM) i1.35%0.24%
Operating Margin (TTM) i-0.39%0.30%
Return on Equity (TTM) i0.02%0.15%
Debt to Equity (MRQ) i0.000.58
Cash & Liquidity
Book Value per Share (MRQ)₹19.09₹580.95
Cash per Share (MRQ)₹1.22₹122.95
Operating Cash Flow (TTM) i₹3.94M₹19.67B
Levered Free Cash Flow (TTM) i₹4.04M₹21.91B
Dividends
Last 12-Month Dividend Yield iN/A0.91%
Last 12-Month Dividend iN/A₹60.00

Valuation & Enterprise Metrics Analysis: Bacil Pharma Ltd. vs Divi's Laboratories Ltd.

MetricBACPHAR (Apr 24, 2026)DIVISLAB (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i118.0067.11
Forward P/E iN/A53.75
PEG Ratio i-0.914.63
Price to Sales (TTM) i154.5616.18
Price to Book (MRQ) i3.0910.82
Market Capitalization
Market Capitalization i₹804.20M₹1.69T
Enterprise Value i₹754.34M₹1.64T
Enterprise Value Metrics
Enterprise to Revenue i137.6815.86
Enterprise to EBITDA i-312.0948.63
Risk & Other Metrics
Beta i0.550.19
Book Value per Share (MRQ) i₹19.09₹580.95

Financial Statements Comparison: Bacil Pharma Ltd. vs Divi's Laboratories Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBACPHAR (2025)DIVISLAB (2025)
Revenue/Sales i093.25B
Cost of Goods Sold i038.70B
COGS % of Revenue i-41.5%
Gross Profit i054.55B
Gross Margin i-58.5%
Research & Development iN/A270.00M
Operating Income (EBIT) i-1.87M25.71B
Operating Margin i-27.6%
EBITDA i-1.29M33.19B
EBITDA Margin i-35.6%
Pre-Tax Income i4.08M29.16B
Pre-Tax Income % of Revenue i-31.3%
Income Tax i34,4607.25B
Income Tax % of Revenue i-7.8%
Net Income (Profit) i4.04M21.91B
Profit Margin i-23.5%

Balance Sheet & Liquidity Metrics

MetricBACPHAR (2025)DIVISLAB (2025)
Cash & Equivalents i28.57M4.15B
Total Current Assets i29.07M100.81B
Total Current Assets % of Revenue i-108.1%
Total Current Liabilities i1.69M14.52B
Total Current Liabilities % of Revenue i-15.6%
Long-Term Debt iN/A20.00M
Long-Term Debt % of Revenue i-0.0%
Total Shareholders Equity i254.31M149.69B
Retained Earnings i114.61M134.00B
Retained Earnings % of Revenue i-143.7%
Property, Plant & Equipment iN/A3.19B

Cash Flow Statement Comparison

MetricBACPHAR (2025)DIVISLAB (2025)
Operating Cash Flow i3.94M19.67B
Operating Cash Flow % of Revenue i-21.1%
Capital Expenditures i0-14.38B
Free Cash Flow i4.01M2.15B
FCF Margin i-2.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBACPHARDIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i14.35M265.47M
Float Shares i3.93M117.72M
% Held by Insiders i81.03%52.04%
% Held by Institutions i0.00%28.65%
% Held by Public i18.97%19.31%

Dividend Analysis & Yield Comparison: Bacil Pharma Ltd. vs Divi's Laboratories Ltd.

MetricBACPHARDIVISLAB
Last 12-Month Dividend iN/A₹60.00
Last 12-Month Dividend Yield iN/A0.91%
3-Year Avg Annual Dividend iN/A₹50.00
3-Year Avg Dividend Yield iN/A0.70%
3-Year Total Dividends iN/A₹150.00
Ex-Dividend DateN/AJul 25, 2025